Iovance Biotherapeutics公司宣布，其创新疗法Iov-5001的研究性新药（IND）申请已获得美国食品药品监督管理局（FDA）的批准。Iov-5001是一种将白细胞介素-12（IL-12）与肿瘤浸润淋巴细胞（TIL）疗法相结合的突破性治疗方案。
此次IND申请的获批，标志着该候选疗法正式进入临床开发阶段。公司计划启动针对实体瘤患者的早期临床试验，以评估Iov-5001的安全性、耐受性及初步疗效。这一进展为Iovance的TIL疗法平台增添了新的重要潜力管线，有望进一步扩展其在肿瘤免疫治疗领域的布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.